235 related articles for article (PubMed ID: 24081576)
21. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
Raval JS; Redner RL; Kiss JE
J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778
[TBL] [Abstract][Full Text] [Related]
22. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
[No Abstract] [Full Text] [Related]
23. Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.
Mahat U; Talati R; Kodish E
Pediatr Blood Cancer; 2019 Jun; 66(6):e27706. PubMed ID: 30854752
[No Abstract] [Full Text] [Related]
24. Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy.
Patil AS; Dotters-Katz SK; Metjian AD; James AH; Swamy GK
Obstet Gynecol; 2013 Aug; 122(2 Pt 2):483-485. PubMed ID: 23884268
[TBL] [Abstract][Full Text] [Related]
25. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
[TBL] [Abstract][Full Text] [Related]
26. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
[TBL] [Abstract][Full Text] [Related]
27. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
[No Abstract] [Full Text] [Related]
28. Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Perera M; Suarez A; Luzardo H; Lopez J; Molero T
Ann Hematol; 2012 Sep; 91(9):1497-8. PubMed ID: 22373551
[No Abstract] [Full Text] [Related]
29. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
Al-Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J
Br J Haematol; 2012 Jan; 156(1):145-7. PubMed ID: 21848881
[No Abstract] [Full Text] [Related]
30. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
Veneri D; Soligo L; Pizzolo G; Ambrosetti A
Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
[No Abstract] [Full Text] [Related]
31. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
[TBL] [Abstract][Full Text] [Related]
32. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
Watanabe R; Tabayashi T; Tomikawa T; Sagawa M; Anan-Nemoto T; Kimura Y; Takahashi Y; Tokuhira M; Otaki S; Oi H; Sawano M; Sugiyama S; Kizaki M
Int J Hematol; 2017 Jan; 105(1):100-103. PubMed ID: 27709451
[TBL] [Abstract][Full Text] [Related]
33. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
34. New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients.
Yoon JS; Lee YJ; Baek DW; Park HY; Park BE; Moon JH; Sohn SK
Korean J Intern Med; 2018 Mar; 33(2):435-437. PubMed ID: 26947025
[No Abstract] [Full Text] [Related]
35. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.
Cines DB; Wasser J; Rodeghiero F; Chong BH; Steurer M; Provan D; Lyons R; Garcia-Chavez J; Carpenter N; Wang X; Eisen M
Haematologica; 2017 Aug; 102(8):1342-1351. PubMed ID: 28411254
[TBL] [Abstract][Full Text] [Related]
36. Management of immune thrombocytopenia--something old, something new.
George JN
N Engl J Med; 2010 Nov; 363(20):1959-61. PubMed ID: 21067388
[No Abstract] [Full Text] [Related]
37. Feasible concomitant treatment with eltrombopag and oral anticoagulation in a patient with chronic immune thrombocytopenia and severe cardiac comorbidities.
Sanchez-Gonzalez B; Ancochea A; Garcia-Pallarols F; Jimenez C; Pedro C; Besses C
Platelets; 2014; 25(4):309-10. PubMed ID: 23444985
[No Abstract] [Full Text] [Related]
38. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
39. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
[TBL] [Abstract][Full Text] [Related]
40. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
Newland A
Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
